189 related articles for article (PubMed ID: 29217774)
1. Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia.
Schneider E; Staffas A; Röhner L; Malmberg ED; Ashouri A; Krowiorz K; Pochert N; Miller C; Wei SY; Arabanian L; Buske C; Döhner H; Bullinger L; Fogelstrand L; Heuser M; Döhner K; Xiang P; Ruschmann J; Petriv OI; Heravi-Moussavi A; Hansen CL; Hirst M; Humphries RK; Rouhi A; Palmqvist L; Kuchenbauer F
Haematologica; 2018 Feb; 103(2):246-255. PubMed ID: 29217774
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells.
Schneider E; Pochert N; Ruess C; MacPhee L; Escano L; Miller C; Krowiorz K; Delsing Malmberg E; Heravi-Moussavi A; Lorzadeh A; Ashouri A; Grasedieck S; Sperb N; Kumar Kopparapu P; Iben S; Staffas A; Xiang P; Rösler R; Kanduri M; Larsson E; Fogelstrand L; Döhner H; Döhner K; Wiese S; Hirst M; Keith Humphries R; Palmqvist L; Kuchenbauer F; Rouhi A
Leukemia; 2020 May; 34(5):1253-1265. PubMed ID: 31768018
[TBL] [Abstract][Full Text] [Related]
3. The endothelin receptor type A is a downstream target of Hoxa9 and Meis1 in acute myeloid leukemia.
Arabanian LS; Johansson P; Staffas A; Nilsson T; Rouhi A; Fogelstrand L; Palmqvist L
Leuk Res; 2018 Dec; 75():61-68. PubMed ID: 30384975
[TBL] [Abstract][Full Text] [Related]
4. Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia.
Mohr S; Doebele C; Comoglio F; Berg T; Beck J; Bohnenberger H; Alexe G; Corso J; Ströbel P; Wachter A; Beissbarth T; Schnütgen F; Cremer A; Haetscher N; Göllner S; Rouhi A; Palmqvist L; Rieger MA; Schroeder T; Bönig H; Müller-Tidow C; Kuchenbauer F; Schütz E; Green AR; Urlaub H; Stegmaier K; Humphries RK; Serve H; Oellerich T
Cancer Cell; 2017 Apr; 31(4):549-562.e11. PubMed ID: 28399410
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.
Staffas A; Arabanian LS; Wei SY; Jansson A; Ståhlman S; Johansson P; Fogelstrand L; Cammenga J; Kuchenbauer F; Palmqvist L
Oncogene; 2017 Mar; 36(11):1516-1524. PubMed ID: 27617578
[TBL] [Abstract][Full Text] [Related]
6. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.
Li Z; Huang H; Chen P; He M; Li Y; Arnovitz S; Jiang X; He C; Hyjek E; Zhang J; Zhang Z; Elkahloun A; Cao D; Shen C; Wunderlich M; Wang Y; Neilly MB; Jin J; Wei M; Lu J; Valk PJM; Delwel R; Lowenberg B; Le Beau MM; Vardiman J; Mulloy JC; Zeleznik-Le NJ; Liu PP; Zhang J; Chen J
Nat Commun; 2012 Feb; 3():688. PubMed ID: 22353710
[TBL] [Abstract][Full Text] [Related]
7. The miR-17∼92 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1.
Mian YA; Zeleznik-Le NJ
Leuk Res; 2016 Jul; 46():51-60. PubMed ID: 27123834
[TBL] [Abstract][Full Text] [Related]
8. Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus.
Wang GG; Pasillas MP; Kamps MP
Blood; 2005 Jul; 106(1):254-64. PubMed ID: 15755900
[TBL] [Abstract][Full Text] [Related]
9. Meis1 supports leukemogenesis through stimulation of ribosomal biogenesis and Myc.
Garcia-Cuellar MP; Prinz A; Slany RK
Haematologica; 2022 Nov; 107(11):2601-2616. PubMed ID: 35546301
[TBL] [Abstract][Full Text] [Related]
10. Flt3 is dispensable to the Hoxa9/Meis1 leukemogenic cooperation.
Morgado E; Albouhair S; Lavau C
Blood; 2007 May; 109(9):4020-2. PubMed ID: 17202314
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development.
Schneider E; Staffas A; Röhner L; Krowiorz K; Heuser M; Döhner K; Bullinger L; Döhner H; Fogelstrand L; Rouhi A; Kuchenbauer F; Palmqvist L
Exp Hematol; 2016 Dec; 44(12):1166-1171. PubMed ID: 27619068
[TBL] [Abstract][Full Text] [Related]
12. Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia.
Bhayadia R; Krowiorz K; Haetscher N; Jammal R; Emmrich S; Obulkasim A; Fiedler J; Schwarzer A; Rouhi A; Heuser M; Wingert S; Bothur S; Döhner K; Mätzig T; Ng M; Reinhardt D; Döhner H; Zwaan CM; van den Heuvel Eibrink M; Heckl D; Fornerod M; Thum T; Humphries RK; Rieger MA; Kuchenbauer F; Klusmann JH
J Clin Oncol; 2018 Apr; 36(10):1007-1016. PubMed ID: 29432078
[TBL] [Abstract][Full Text] [Related]
13. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias.
Lawrence HJ; Rozenfeld S; Cruz C; Matsukuma K; Kwong A; Kömüves L; Buchberg AM; Largman C
Leukemia; 1999 Dec; 13(12):1993-9. PubMed ID: 10602420
[TBL] [Abstract][Full Text] [Related]
14. MEIS1 and HOXA7 genes in human acute myeloid leukemia.
Afonja O; Smith JE; Cheng DM; Goldenberg AS; Amorosi E; Shimamoto T; Nakamura S; Ohyashiki K; Ohyashiki J; Toyama K; Takeshita K
Leuk Res; 2000 Oct; 24(10):849-55. PubMed ID: 10996203
[TBL] [Abstract][Full Text] [Related]
15. HOXA9 modulates its oncogenic partner Meis1 to influence normal hematopoiesis.
Hu YL; Fong S; Ferrell C; Largman C; Shen WF
Mol Cell Biol; 2009 Sep; 29(18):5181-92. PubMed ID: 19620287
[TBL] [Abstract][Full Text] [Related]
16. Deregulation of the HOXA9/MEIS1 axis in acute leukemia.
Collins CT; Hess JL
Curr Opin Hematol; 2016 Jul; 23(4):354-61. PubMed ID: 27258906
[TBL] [Abstract][Full Text] [Related]
17. HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia.
Zhu G; Luo H; Feng Y; Guryanova OA; Xu J; Chen S; Lai Q; Sharma A; Xu B; Zhao Z; Feng R; Ni H; Claxton D; Guo Y; Mesa RA; Qiu Y; Yang FC; Li W; Nimer SD; Huang S; Xu M
Nat Commun; 2021 Mar; 12(1):1956. PubMed ID: 33782403
[TBL] [Abstract][Full Text] [Related]
18. Meis2 as a critical player in MN1-induced leukemia.
Lai CK; Norddahl GL; Maetzig T; Rosten P; Lohr T; Sanchez Milde L; von Krosigk N; Docking TR; Heuser M; Karsan A; Humphries RK
Blood Cancer J; 2017 Sep; 7(9):e613. PubMed ID: 28960191
[TBL] [Abstract][Full Text] [Related]
19. A Multiplex CRISPR-Screen Identifies PLA2G4A as Prognostic Marker and Druggable Target for HOXA9 and MEIS1 Dependent AML.
Hassan JJ; Lieske A; Dörpmund N; Klatt D; Hoffmann D; Kleppa MJ; Kustikova OS; Stahlhut M; Schwarzer A; Schambach A; Maetzig T
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502319
[No Abstract] [Full Text] [Related]
20. Dangerous liaisons: cooperation between Pbx3, Meis1 and Hoxa9 in leukemia.
Thorne RM; Milne TA
Haematologica; 2015 Jul; 100(7):850-3. PubMed ID: 26130510
[No Abstract] [Full Text] [Related]
[Next] [New Search]
